默克集团公布2024年全年营收

Core Viewpoint - Merck Group reported a recovery in profit growth for 2024, driven by strong performance in healthcare, life sciences, and electronics businesses, achieving full-year expectations [1][2] Group 1: Financial Performance - In 2024, Merck Group's net sales reached €21.2 billion (approximately ¥166.7 billion), with an organic growth of 2.0% [1] - EBITDA is projected to increase to €6.1 billion (approximately ¥48 billion), with an organic growth of 6.9% [1] - By business segment, life sciences net sales were €8.9 billion (approximately ¥70 billion), a year-on-year decline of 3.3%; healthcare net sales were approximately €8.5 billion (approximately ¥66.9 billion), a year-on-year increase of 7.0%; electronics net sales were approximately €3.8 billion (approximately ¥29.9 billion), a year-on-year increase of 4.6% [1] Group 2: Business Segment Insights - The growth in the electronics business was primarily driven by semiconductor solutions, with demand for semiconductor materials increasing due to widespread applications of artificial intelligence [1] - Sales in the semiconductor solutions segment rose to €2.6 billion (approximately ¥20.4 billion), with an organic growth of 7.8% [1] - Display solutions and surface solutions segments reported sales of €748 million (approximately ¥5.88 billion) and €406 million (approximately ¥3.19 billion), respectively [1] Group 3: Future Outlook - For 2025, Merck expects net sales to be between €21.5 billion and €22.9 billion (approximately ¥169.1 billion to ¥180.1 billion) [2] - EBITDA is forecasted to be between €6.1 billion and €6.6 billion (approximately ¥48 billion to ¥51.9 billion) [2]